MedTrace Logo

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

NCT03291067 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2026-01-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.

Conditions

  • Menopause Hot Flashes

Interventions

DRUG

MT-8554 1mg

MT-8554 1mg QD, oral, 12 weeks

DRUG

MT-8554 5mg

MT-8554 5mg QD, oral, 12 weeks

DRUG

MT-8554 10mg

MT-8554 10mg QD, oral, 12 weeks

DRUG

Placebo

Placebo QD, oral, 12 weeks

Sponsors & Collaborators

  • Tanabe Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Head of Medical Science · Tanabe Pharma America, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2018-10-19
Completion
2018-11-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03291067 on ClinicalTrials.gov